Viatris Inc at Citi BioPharma Conference (Virtual) Transcript
Hi. Good morning, everyone. This is Navann Ty. I cover spec pharma at Citi, including Viatris. So Viatris is the combination of Mylan and Pfizer spin-off Upjohn business. And today, I have the pleasure of having with me Michael Goettler, who's the CEO of Viatris; Rajiv Malik, the President; and Bill Szablewski, the Head of Capital Markets.
So before I start the Q&A, I'll just hand over to Bill for forward-looking statement.
Yes. Thank you, Navann, and good morning, everybody. During today's discussion, we may make forward-looking statements on a number of matters. These forward-looking statements are subject to risks and uncertainty that could cause future results or events to differ materially from today's projections and discussion. Please refer to our SEC filings for a fuller explanation of those risks and uncertainties and the limits applicable to the forward-looking statements. Also, during today's discussion, we will not be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
